ロード中...
Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study
Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response. The long-term mortality rate of steroid-refr...
保存先:
主要な著者: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
Taylor & Francis Group
2017-03-01
|
シリーズ: | OncoImmunology |
主題: | |
オンライン・アクセス: | http://dx.doi.org/10.1080/2162402X.2016.1277307 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|